Search
efbemalenograstim alfa-vuxw (Ryzneuta)
Indications:
- treatment of cytotoxic chemotherapy induced neutropenia
Contraindications:
- serious allergic reactions to granulocyte stimulating factor
- efbemalenograstim alfa, pegfilgrastim, filgrastim
* pregnancy: insufficient data
Dosage:
- 20 mg SC once per chemotherapy cycle
- given at least 24 hr after cytotoxic chemotherapy
- do not administer within 14 days before or < 24 hr after administration of cytotoxic chemotherapy
20 mg/mL prefilled syringe
Adverse effects:
- nausea (51%)
- anemia (15%)
- thrombocytopenia (12%
Mechanism of action:
- granulocyte colony-stimulating factor
General
pharmaceutical growth factor
granulocyte colony-stimulating factor; colony-stimulating factor 3; G-CSF; pluripoietin (CSF3, C17orf33, GCSF)
References
- Medscape: efbemalenograstim alfa (Rx)
https://reference.medscape.com/drug/ryzneuta-efbemalenograstim-alfa-4000231